Invitrogen™ Human beta Amyloid (1-40) Recombinant Protein

Catalog No.	Quantity
03-138	1 mg

Catalog No. 03-138 Supplier Invitrogen™ Supplier No. 03138

Description

Recombinant Protein

Human beta Amyloid (1-40) Recombinant Protein for Bioactivity

Beta-amyloid is a 40-43 amino acid peptide cleaved from amyloid precursor protein, and a putative gamma-secretase. Amyloid beta (1-40) together with Amyloid beta (1-42) are two major C-terminal variants of the amyloid beta protein, constituting the majority of amyloid beta proteins. Both the amyloid beta (40) and amyloid beta (42) alloforms are major components of the extracellular plaques found in Alzheimer's disease brain tissue.

Specifications

• Accession Number: P05067
• For Use With (Application): Bioactivity
• Formulation: Protein with no preservative
• Gene ID (Entrez): 351
• Molecular Weight (g/mol): 4.3 kDa
• Name: Human beta Amyloid (1-40)
• Purification Method: Purified
• Quantity: 1 mg
• Storage Requirements: -20°C
• Regulatory Status: RUO
• Gene Alias: A beta 1 40; A β 1 40; A4; AAA; AB40; Abeta; Abeta40; Abeta42; ABPP; AD1; Adap; AG; AICD-50; AICD-57; AICD-59; AID(50); AID(57); AID(59); Alpha-CTF; Alpha-secretase C-terminal fragment; Alzheimer disease amyloid A4 protein homolog; alzheimer disease amyloid protein; Amyloid; Amyloid b; Amyloid beta; amyloid beta (A4) precursor protein; Amyloid beta 1 40; amyloid beta A4 protein; amyloid beta precursor protein; Amyloid intracellular domain 50; Amyloid intracellular domain 57; Amyloid intracellular domain 59; Amyloid precursor protein; Amyloid β; Amyloid-beta A4 protein; Amyloid-beta precursor protein; Amyloid-beta protein 40; Amyloid-beta protein 42; Amyloidogenic glycoprotein; App; APP-C57; APP-C59; APP-C99; APPI; appican; Aβ 1 40; B APP40; BAPP40; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); beta-amyloid precursor protein; betaApp; BetaAPP40; Beta-APP40; Beta-APP42; Beta-CTF; Beta-secretase C-terminal fragment; C31; C80; C83; C99; Cerebral vascular amyloid peptide; CTFgamma; CVAP; E030013M08Rik; Gamma-CTF(50); Gamma-CTF(57); Gamma-CTF(59); Gamma-secretase C-terminal fragment 50; Gamma-secretase C-terminal fragment 57; Gamma-secretase C-terminal fragment 59; N-APP; P3(40); P3(42); peptidase nexin-II; PN2; PN-II; PreA4; protease nexin II; protease nexin-II; S-APP-alpha; S-APP-beta; Soluble APP-alpha; Soluble APP-beta; β APP40; βAPP40; testicular tissue protein Li 2
• Common Name: Amyloid beta 40
• Gene Symbol: APP
• Product Type: Protein
• Conjugate: Unconjugated
• Species: Human
• Recombinant: Recombinant
• Sequence: H2N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-ValPhe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH
• Content And Storage: -20°C
• Shipping Condition: Dry Ice
• Expression System: proprietary
• Form: Lyophilized
• Protein Subtype: Amyloid-Related Proteins, Neuropeptides
• Research Category: Neurobiology
• Purity or Quality Grade: ≥98% by HPLC

Frequently Asked Questions (FAQs)

How do you recommend that beta amyloid peptide be reconstituted?

Recommendations for Beta Amyloid Peptide Reconstitution:
(1) To induce peptide aggregation for neurotoxicity studies: The appearance of toxicity has recently been shown to correlate to the extent of beta sheet structure (S. Wang et al. [2001] J. Biol. Chem. 276(45):42027-42034). Recommended preincubation is: Dissolve the lyophilized peptide in 0.1% (v/v) trifluoroacetic acid in water at 10 mg/mL. Dilute the peptide to 0.5-1.0 mg/mL with PBS (without Ca2+). Incubate at 25°C for 24-48 hrs (24-36 hrs is usually sufficient). Neurotoxic activity is usually observed at 30-100 micrograms/mL.
(2) To prepare peptide for studies which require minimal peptide aggregation: Dissolve the peptide at a concentration of 1 mg/mL in 100% HFIP (1,1,1,3,3,3-hexafluoro-2-propanol [Sigma-Aldrich Cat. No. 325244, 99.8% ACS reagent grade]). Incubate at RT for 2 hours. During the incubation, vortex the peptide solution several times at moderate speed, allowing the HFIP to cover as much of the surface area as possible. Dry down the HFIP/peptide solution under a gentle stream of nitrogen gas. Continue drying for an additional 10 minutes. Cap vial immediately. Resuspend the peptide in 100% DMSO. Incubate the peptide plus DMSO for 12 minutes at RT with periodic vortexing at moderate speed. Add 10 microliters of this DMSO/peptide solution dropwise to 10 mL of BSAT-DPBS (see formulation below) while vortexing at moderate speed. Peptides prepared in this manner have been used as standards in ELISA for the detection of beta amyloid in biological samples. When using this peptide in ELISA, it is important that the assay buffer used with the peptide standards has the same composition as the samples under investigation.
Buffer Formulations: DPBS Solution (10X Stock) (Gibco#14200-075) Dulbecco's PBS (DPBS w/o Mg2+, Ca2+) BSAT-DPBS Solution: 1X DPBS, pH 7.4 5% BSA 0.03% Tween-20

Note: The inclusion of a protease inhibitor (i.e. AEBSF [Sigma Cat. No. A-8456]) is recommended when the BSAT-BPBS solution is to be used for the analysis beta amyloid-containing biological samples. To prepare a 40 mM stock solution of AEBSF, add 100 mg of AEBSF to 10 mL DPBS, pH 7.4, containing 5% BSA. The stock solution should be diluted to a concentration of 1 mM AEBSF in BSAT-DPBS just prior to use.